Urinary leukotriene E-4/exhaled nitric oxide ratio and montelukast response in childhood asthma

作者：Rabinovitch Nathan; Graber Nora J; Chinchilli Vernon M; Sorkness Christine A; Zeiger Robert S; Strunk Robert C; Bacharier Leonard B; Martinez Fernando D; Szefler Stanley J^*

来源：Journal of Allergy and Clinical Immunology, 2010, 126(3): 545-U239.

DOI：10.1016/j.jaci.2010.07.008

• Asthma
• biomarkers
• fluticasone propionate
• inhaled corticosteroids
• leukotriene E-4
• montelukast

Background: A subset of children with asthma respond better to leukotriene receptor antagonists than to inhaled corticosteroids. Information is needed to identify children with these preferential responses.
Objective: We sought to determine whether the ratio of urinary leukotriene E-4 (LTE4) to fractional exhaled nitric oxide (FENO) delineates children with preferential responsiveness to montelukast compared with fluticasone propionate (FP) therapy.
Methods: Data from 318 children with mild-to-moderate asthma enrolled in 2 National Heart, Lung, and Blood Institute Childhood Asthma Research and Education Network studies (Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid [CLIC] and the Pediatric Asthma Controller Trial [PACT]) were analyzed. The association between LTE4/FENO ratios at baseline and improved lung function or asthma control days (ACDs) with montelukast and FP therapy was determined, and phenotypic characteristics related to high ratios were assessed.
Results: LTE4/FENO ratios were associated with a greater response to montelukast than FP therapy for FEV1 measurements (2.1% increase per doubling of ratio, P = .001) and for ACDs per week (0.3-ACD increase, P = .009) in the CLIC study. In PACT the ratio was associated with greater FEV1 responsiveness to montelukast than FP therapy (0.6% increase, P = .03). In a combined study analysis, LTE4/FENO ratios were associated with greater response to montelukast than FP therapy for FEV1 (0.8% increase, P = .0005) and ACDs (0.3-ACD increase, P = .008). Children with LTE4/FENO ratios at or above the 75th percentile were likely (P <.05) to be younger and female and exhibit lower levels of atopic markers and methacholine reactivity.
Conclusion: LTE4/FENO ratios predict a better response to montelukast than FP therapy in children with mild-to-moderate asthma. (J Allergy Clin Immunol 2010;126:545-51.)

• 出版日期2010-9